Interaction of Bupropion with 5-HT3A Receptors

Abstract

For more than two decades, bupropion has been clinically prescribed for the treatment of depression (Wellbutrin®), and more recently for smoking cessation (Zyban®). Bupropion is conventionally described as a dual norepinephrine dopamine reuptake inhibitor, therefore effective as an antidepressant. However, we and others have shown that it also interacts with receptors of the Cys-loop superfamily, namely neuronal nicotinic acetylcholine receptors. In the continuum of exploring the molecular interactions of bupropion with other prominent members of the Cys-loop superfamily, we report here that bupropion additionally inhibits 5-hydroxytryptamine (serotonin) type 3A receptors (5-HT3ARs).5-HT3ARs are cation-conducting, homo-pentameric ligand-gated ion channels of the Cys-loop superfamily which are structurally and functionally distinct from other serotonin receptors that are G-proteins. 5-HT3 receptors are current targets for anti-emetics mainly used in cancer chemotherapy, as well as potential future targets for disorders including anxiety, schizophrenia, and Alzheimer's disease.Here we characterized our newly-identified interaction of bupropion with 5-HT3ARs with electrophysiological and radioligand binding studies. In oocytes, bupropion inhibited 5-HT3AR-mediated currents with an IC50 value of 87 µM (nH = 1.2). That 300 µM bupropion inhibited [3H]-5-HT or [3H]-granisetron (a competitive antagonist) binding by ∼ 20% indicated at best weak interaction with the agonist binding site. In contrast, the effect of different concentrations of bupropion on serotonin concentration-response curves suggested a non-competitive nature of interaction. Along these lines, importantly, the inhibition of serotonin-evoked currents recorded from oocytes was proportional to the length of preincubation time with bupropion.In summary, our results are indicative of a negative allosteric interaction of bupropion with the 5-HT3AR. Currently, experiments are underway to identify the site(s) of interaction for bupropion within the 5- HT3AR.